Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin versus placebo with pemetrexed as second-line therapy for advanced or metastatic non-small cell lung cancer
2006-006698-25Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Enzastaurin + pemetrexed with Placebo + pemetrexed (2 arms). Primary endpoint: Progression-free survival time. Started Jun 2007; status: terminated.
02
Drugs
enzastaurinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-006698-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006698-25.